Tesamorelin dosing reference

Tesamorelin (also marketed as Egrifta®) is a peptide in the Growth Hormone category. It is a research peptide and is not FDA-approved for human use. The dose ranges shown (1–2 mg) are summarized from peer-reviewed research literature where evidence is preliminary.

Tesamorelin most commonly ships in 1, 2, 5 mg vials. Typical reconstitution volumes are 1, 2, 3 ml of bacteriostatic water — choose the volume to land on a syringe-friendly unit count for your target dose.

Use the formula concentration = vial mg ÷ BAC water ml, then volume = dose mg ÷ concentration, then units = volume × 100 (for U-100). For example, a 1 mg vial reconstituted with 1 ml gives 1.00 mg/ml — at the typical low dose of 1 mg that resolves to 100.0 units. The free reconstitution calculator on this site verifies the math against your specific vial.

No. Tesamorelin is a research peptide and is not FDA-approved for human use in the United States as of April 2026. Any use must come through a licensed healthcare provider, typically via a compounding pharmacy.

Side-effect profiles for research peptides are characterized in published research rather than an FDA label. Most users report mild local reactions at the injection site, occasional fatigue, and headache in the first few doses. Long-term human safety data is limited for most research compounds. Discuss with your prescribing provider before starting.

No. The values shown are reference numbers summarized from authoritative sources — FDA-approved labels for approved compounds and peer-reviewed research for the rest. They are not personalized recommendations. Always follow your prescribing provider's instructions and verify every calculation against your vial label.